Cancer ResearchResearch PaperPaywall

NAMPT inhibitors kill glioblastoma stem cells at picomolar doses while sparing healthy brain cells

In lab-grown human cells, NAMPT inhibitors killed glioblastoma stem cells at nanomolar or picomolar doses and spared neurons and vascular cells until micromolar doses.

Friday, November 20, 2026 1 view
Published in Biomed Pharmacother
A researcher pipetting into a multi-well cell culture plate under a laminar flow hood in a neuro-oncology lab

Summary

Glioblastoma, an aggressive brain cancer, usually returns after surgery, radiation and chemotherapy, largely because resistant stem-like tumor cells survive. This lab study asked whether those stem cells depend on one NAD-making enzyme, NAMPT. Patient-derived glioblastoma stem cells had high NAMPT and almost no backup enzyme (NAPRT), so they rely on a single route to make NAD, a molecule cells need for energy and survival. Drugs that block NAMPT triggered cell death in these stem cells at nanomolar or picomolar concentrations. Healthy human astrocytes, endothelial cells and differentiated neurons tolerated doses up to the micromolar range. Standard glioblastoma cell lines were much less sensitive. Silencing the NAMPT gene reproduced the drug effect. This is cell-culture work only, with no animals or patients. Earlier clinical trials of systemic NAMPT inhibitors failed because of toxicity, so the authors propose using them as targeted post-operative tools rather than broad treatments. That idea still has to be tested in living models. This summary is based on the abstract only.

Detailed Summary

Glioblastoma is among the deadliest brain cancers, and it nearly always returns after surgery, radiation and chemotherapy. Recurrence is largely driven by glioma stem cells, which resist standard treatment. Finding a metabolic weakness in these cells matters for cancer, and the work also bears on NAD biology, which longevity researchers watch closely.

NAMPT is the rate-limiting enzyme in the salvage pathway that recycles nicotinamide into NAD, a coenzyme central to energy metabolism and DNA repair. Earlier clinical trials of systemic NAMPT inhibitors failed because of severe toxicity and limited effect on bulk tumor. This study asked whether the drugs could be repurposed to target stem cells specifically, to prevent relapse rather than shrink the primary tumor.

The researchers compared patient-derived glioblastoma stem cells, standard glioblastoma cell lines, and non-malignant human cells: astrocytes, endothelial cells and differentiated neurons. They measured NAMPT expression, metabolic dependence, cytotoxicity and apoptosis, and used gene silencing to confirm the target.

The stem cells had high NAMPT and negligible NAPRT, the enzyme that offers an alternative NAD route, so they depend strictly on the salvage pathway. Synthetic NAMPT inhibitors induced apoptosis in them at nanomolar or picomolar concentrations. Non-malignant neural and vascular cells tolerated doses up to the micromolar range. Standard cell lines were far less sensitive and did not reflect the stem cell response. Silencing NAMPT mimicked the drug toxicity, supporting an on-target effect.

The authors suggest a therapeutic window, with NAMPT inhibitors used after surgery to clear residual stem cells. This is a mechanism and cell-viability result only.

Caveats: the work used cultured cells, with no animal or human data and no tumor-recurrence or survival endpoint. Prior trial toxicity remains a concern, and delivery to the brain was not addressed. The summary relies on the abstract alone.

Key Findings

  • Patient-derived glioblastoma stem cells had high NAMPT and negligible NAPRT, making them dependent on the NAD salvage pathway (cell-culture finding).
  • NAMPT inhibitors induced apoptosis in glioblastoma stem cells at nanomolar or picomolar concentrations in vitro.
  • Non-malignant astrocytes, endothelial cells and differentiated neurons tolerated doses up to the micromolar range, indicating a selectivity window.
  • Standard glioblastoma cell lines were much less sensitive, so they poorly model stem cell drug responses.
  • NAMPT gene silencing reproduced inhibitor toxicity, supporting on-target action; no animal, recurrence or survival data were reported.

Methodology

In vitro study comparing patient-derived glioblastoma stem cells, standard glioblastoma lines and non-malignant human astrocytes, endothelial cells and differentiated neurons. Small-molecule NAMPT inhibitors were tested for cytotoxicity, apoptosis and selectivity, with enzyme-silencing experiments to confirm target specificity. Sample sizes and specific compounds were not stated in the abstract.

Study Limitations

The summary is based on the abstract only, so details on compounds, sample sizes, replicates and statistics were unavailable. Findings come from cultured cells with no in vivo model, no recurrence or survival endpoint, and no data on brain delivery or systemic toxicity. The selectivity window was shown in a limited set of non-malignant cell types.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: